Phaseline

Targets › CAG

CAG: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Apr 2028.

Open in Phaseline: the race on CAG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vico Therapeutics B. V.VO659
Antisense oligonucleotide targeting CAG repeats
CAGPhase 1Spinocerebellar Ataxia Type 1Apr 2028

Conditions

Spinocerebellar Ataxia Type 1 (1)

Modalities

small molecule (1)

Companies

Vico Therapeutics B. V. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.